Research & Development: Page 18
-
With market success at stake, can tech help solve the diversity problem in clinical trials?
Diversity in clinical trials isn’t only important for the health of the overall patient population — it can save millions in lost profits.
By Kelly Bilodeau • Aug. 24, 2022 -
Podcast
Woman of the Week: Glympse Bio’s Dr. Tram Tran
How the chief medical officer of the emerging diagnostic company is using the patient perspective as a guiding light.
By Taren Grom • Aug. 24, 2022 -
Trendline
Clinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Overcoming mental health’s drug development challenges with AI
PsychoGenics is leveraging AI-driven drug discovery platforms to advance mental health treatments for schizophrenia, bipolar disorder and treatment-resistant depression.
By Kelly Bilodeau • Aug. 23, 2022 -
Q&A // First 90 Days
First 90 Days: Agios Pharmaceuticals’ Brian Goff
The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.
By Alexandra Pecci • Aug. 22, 2022 -
Podcast
Woman of the Week: Takeda Oncology’s Teresa Bitetti
Upon joining Takeda Pharmaceuticals as president of the global oncology unit, Teresa Bitetti had two important goals: to transform the business and create greater synergies between commercial and R&D operations.
By Taren Grom • Aug. 17, 2022 -
Inventing the COVID vax pill: a matter of convenience and durability
Recent data from Vaxart’s phase 1 trial of its COVID-19 inoculation pill shows potential.
By Kelly Bilodeau • Aug. 17, 2022 -
The CEO in the ophthalmologist’s coat
In balancing two roles — Lexitas CEO and practicing physician — George Magrath brings a patient-first perspective to developing and advancing eye treatments.
By Alexandra Pecci • Aug. 16, 2022 -
Right under our noses: Could COVID-19 vaccines be better as nasal spray?
Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.
By Kelly Bilodeau • Aug. 16, 2022 -
Q&A
How real world evidence is impacting rare disease drug development
ICON’s Will Maier shares how a more patient-focused approach to trials is leading to alternatives for randomization.
By Kim Ribbink • Aug. 9, 2022 -
Turning harp seal contraceptives into a ‘new genre’ of cancer treatments
With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.
By Alexandra Pecci • Aug. 9, 2022 -
The ‘alarming’ spread of Monkeypox — by the numbers
With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’
By Meagan Parrish • Aug. 8, 2022 -
Making Moves
Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires
How these latest executive personnel changes are impacting the industry.
By Karissa Waddick • Aug. 3, 2022 -
Taking probiotics where they’ve never gone before
How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.
By Karissa Waddick • Aug. 2, 2022 -
‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients
EverythingALS aims to speed drug development through improved diagnostics.
By Kelly Bilodeau • Aug. 2, 2022 -
Q&A
How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond
WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.
By Kim Ribbink • Aug. 1, 2022 -
Q&A
Personalized data could bring PhysIQ to the forefront of clinical trial evolution
The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.
By Karissa Waddick • July 28, 2022 -
What’s next for Biogen? Here’s what executives are saying
A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?
By Michael Gibney • July 27, 2022 -
Q&A
Lupus discovery lends clues to the fight against long COVID
So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki could help lead the way.
By Kelly Bilodeau • July 27, 2022 -
Podcast
Woman of the Week: Applied BioMath's Katie Williams
The 2022 president of Women in Bio is equal parts math and gender parity evangelist.
By Taren Grom • July 27, 2022 -
The earlier the better: New consortium leverages infant screening to accelerate treatment
Inozyme Pharma has joined a genomic sequencing program developing a novel rapid test for 388 genetic diseases.
By Kim Ribbink • July 25, 2022 -
A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets
The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?
By Michael Gibney • July 25, 2022 -
Q&A
Behind Pfizer's new quest to target a 'transformation' in pharma
A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.
By Kelly Bilodeau • July 25, 2022 -
Moderna's next vax target? A little-known cause of birth defects
How the mRNA-based biotech is developing the first-ever prophylactic for a devastating virus.
By Karissa Waddick • July 21, 2022 -
By the numbers: The rising danger of superbugs
A look at how the COVID-19 pandemic exacerbated one of the world’s greatest public health concerns.
By Karissa Waddick • July 20, 2022 -
Podcast
Woman of the Week: Vaxxinity's Mei Mei Hu
Mei Mei Hu is looking to lead a third biologic ‘revolution’ by developing vaccines for chronic diseases.
By Taren Grom • July 20, 2022